Floatz logo

rc48-adc

Carcinoma of Unknown Primary

SOLTI Breast Cancer Research Groupantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Carcinoma of Unknown Primary cohort.

Asset / SponsorPhaseRating
Amifostine
M.D. Anderson Cancer Center
Phase 2B
Tislelizumab
SOLTI Breast Cancer Research Group
Phase 2B
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
Pyrotinib
SOLTI Breast Cancer Research Group
Phase 2CCC
Spartalizumab
SOLTI Breast Cancer Research Group
Phase 2CC

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →